how to join retatrutide trial Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical The numbers from Lilly's Phase

New trial data for Amgen's GLP-1 drug MariTide shows a weight loss of 20 percent in non-diabetic participants with obesity or overweight.

While the absolute risk increase was modest, our findings point to an important potential adverse effect that clinicians should consider, especially in patients with predisposing factors for GERD

Uncover the link, potential causes, and treatment options to help alleviate your discomfort effectively.

Weight loss solutions with compounded GLP-1 medications like Semaglutide and Tirzepatide

What It Means, What To Do, and When Its Dangerous

Coronary artery disease (CAD)cardiovascular condition occuring due to atherosclerotic plaque accumulation in the epicardial arteriesis responsible for disa...